Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Open accessAbstract
Alzheimer's disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sodium oligomannate suppressed neuroinflammation, Aβ plaque deposition, and cognition impairment.
“The usage of a sodium oligomannate, with known cognition improvement effect in humans, suppressed neuroinflammation, Aβ plaque deposition, and cognition impairment (164).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 231 · Cited by 136
- Authors
- Dong, Y., Li, X., Cheng, J., & Hou, L.
- Affiliations
- Qingdao University (CN)
- Beijing Institute for Brain Disorders (CN)
- Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (CN)
- Corresponding author
- Cheng, Jinbo
- Hou, Lin
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-28
- Volume
- 20
- Issue
- 3
- Pages
- 558
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6386861
- OpenAlex
- W2913278535
- Cited by
- 136
- References
- 231
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 11 · 2023: 24 · 2022: 29 · 2021: 22 · 2020: 24 · 2019: 4 · 2018: 1
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- China Postdoctoral Science Foundation (2017M622142)
- Special Fund for Post-doctoral Innovative Projects in Shandong Province of China (201703029)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development, microglia, neuroinflammation, amyloid-beta, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, anti-Alzheimer agents, dementia
- MeSH terms
- Drug Development, Alzheimer Disease, Brain, Humans, Inflammation, Drug Delivery Systems, Microglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
